Short-term adjuvant therapy with Terminalia arjuna attenuates ongoing inflammation and immune balance in patients with stable coronary artery disease: In vitro and in vivo evidence.  

In a 2015 placebo-controlled trial, 116 patients with stable coronary artery disease were given either 500 mg T. arjuna twice daily, or a placebo. After three months of treatment, arjuna therapy significantly down-regulated triglycerides, very-low-density lipoprotein (VLDL) cholesterol and other inflammatory markers compared to placebo.    

References:

Kapoor D, Trikha D, Vijayvergiya R, et al. (2015). Short-term adjuvant therapy with Terminalia arjuna attenuates ongoing inflammation and immune balance in patients with stable coronary artery disease: in vitro and in vivo evidence. J Cardiovasc Transl Res. 8(3): 173-86